Table 1:

Single agent targeted therapies approved for genomically altered cancers (mutation, amplification or fusion) and response rates^*

Solid tumors: Fusion target
Drug	Disease Indication	Line of Therapy	Aberrant gene	Number of studies**	Response Rate (%)**
Alectinib	NSCLC	2+	ALK	1	79%
Brigatinib	NSCLC	2+	ALK	1	53%
Ceritinib	NSCLC	2+	ALK	1	73%
Crizotinib	NSCLC	1	ALK/ROS1	2	56%
Entrectinib	Solid tumors	1+	NTRK/ROS1/ALK	1	78%
Larotrectinib	Solid tumors	1+	NTRK	1	75%
Solid tumor: Non-fusion target
Drug	Disease Indication	Line of Therapy	Aberrant gene	Number of studies**	Response Rate (%)
Afatinib	NSCLC	1+	EGFR	1	50%
Dabrafenib	Melanoma	1+	BRAF	1	54%
Dacomitinib	NSCLC	1+	EGFR	1	75%
Erlotinib	NSCLC	1+	EGFR	1	65%
Gefitinib	NSCLC	1	EGFR	1	70%
Imatinib	GIST	1	KIT	1	51%
Olaparib	Ovarian	4+	BRCA	1	34%
Osimertinib	NSCLC	1+	EGFR	1	51%
Rucaparib	Ovarian	3+	BRCA	1	54%
Talazoparib	Breast	2+	BRCA	1	50%
TDM-1	Breast	2+	HER2	1	44%
Trastuzumab	Breast	2+	HER2	1	14%
Vemurafenib	Melanoma	1+	BRAF	1	48%
Hematologic malignancies: Fusion Target
Drug	Disease Indication	Line of Therapy	Aberrant gene	Number of studies**	Response Rate (%)
All trans-retinoic acid	APL	1+	PML-RARA	1	72%
Bosutinib	CML	2+	BCR-ABL	2	31%
Dasatinib	CML	1+	BCR-ABL	2	63%
Imatinib	CML	1	BCR-ABL	1	73%
Nilotinib	CML	1+	BCR-ABL	1	84%
Ponatinib	CML	2+	BCR-ABL	1	46%
Hematologic malignancies: Target non-fusion
Drug	Disease Indication	Line of Therapy	Aberrant gene	Number of studies**	Response Rate (%)
Enasidenib	AML	2+	IDH2	1	23%
Gilteritinib	AML	2+	FLT3	1	21%
Ivosidenib	AML	2+	IDH1	1	33%
Vemurafenib	ECD	1+	BRAF	1	55%

^*Approved by the Food and Drug Administration (FDA)

^**Refers to number of studies provided in FDA package insert; Response rate is per package insert. If more than one study listed, the mean is given

Abbreviations: AML=acute myelogenous leukemia; CML=chronic myelogenous leukemia; ECD=Erdheim-Chester disease; NHL=non-Hodgkin’s lymphoma; NSCLC=non-small cell lung cancer